SEP 1 1 2003

PTO/SB/22 (08-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through 7/31/2006. OMB 0651-0031

Approved for use thr

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)			D	Docket No. (Optional) 27656/37082		
In re Application of Frey et al.						
	Application Number 09/762,871		Filed March 26, 2001			
-	CONJUGATES OF DNA INTERACTING GROUPS WITH For: STEROID HORMONES FOR USE AS NUCLEIC ACID TRANSFECTION AGENTS					
	Art Unit 1616 Exam			iner B. Badio, Ph.D.		
This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.						
The requested extension and appropriate non-small-entity fee are as follows (check time period desired):						
One month (37 CFR 1.17(a)(1))				\$		
x Two months (37 CFR 1.17(a)(2))				\$	410.00	
Three months (37 CFR 1.17(a)(3))				\$	•	
Four months (37 CFR 1.17(a)(4))				\$		
Five months (37 CFR 1.17(a)(5))				\$		
Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is						
reduced by one-half, and the resulting fee is: \$						
x A check in the amount of the fee is enclosed.						
Payment by credit card. Form PTO-2038 is attached.						
The Director has already been authorized to charge fees in this application to a Deposit Account.						
The Director is hereby authorized to charge any fees which may be required, or credit any						
overpayment, to Deposit Account Number13-2855						
I have enclosed a duplicate copy of this sheet.						
I am the applicant/inventor.						
assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).						
attorney or agent of record. Registration Number						
attorney or agent under 37 CFR 1.34(a).						
Registration number if acting under 37 CFR 1.34(a) 40,725						
September 9, 2003 Date Signature Signature						
(312) 474-6300 William K. Merkel						
Telephone Number Typed or printed name NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more						
than one signature is required, see below						
Total of 1	forms are submitted.					

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: September 9, 2003